PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDronabinol
Dronabinol
Dronabinol, Marinol (dronabinol) is a small molecule pharmaceutical. Dronabinol was first approved as Marinol on 1985-05-31. It is used to treat anorexia, nausea, and vomiting in the USA. The pharmaceutical is active against cannabinoid receptor 1. In addition, it is known to target N-arachidonyl glycine receptor, glycine receptor subunit alpha-1, glycine receptor subunit alpha-2, cannabinoid receptor 2, transient receptor potential cation channel subfamily A member 1, G-protein coupled receptor 55, glycine receptor subunit alpha-3, transient receptor potential cation channel subfamily V member 2, and transient receptor potential cation channel subfamily M member 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dronabinol, Marinol (discontinued: Dronabinol, Syndros)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dronabinol
Tradename
Company
Number
Date
Products
MARINOLAlkem LaboratoriesN-018651 RX1985-05-31
3 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dronabinolANDA2025-01-07
just cbd - cbd and thc ultra reliefC2002632024-04-23
marinolNew Drug Application2023-02-14
syndrosNew Drug Application2024-05-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
vomitingHP_0002013D014839R11.1
nauseaHP_0002018D009325R11.0
anorexiaHP_0002039D000855R63.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dronabinol, Syndros, Benuvia Operations
82222922028-08-06DS, DP
93457712028-08-06DS, DP
102652932028-08-06DS, DP
112534722028-08-06DS, DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD10: Dronabinol
HCPCS
Code
Description
Q0167
Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Clinical
Clinical Trials
574 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Biological availabilityD001682——1————1
Substance-related disordersD019966EFO_0003890F131————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDronabinol
INNdronabinol
Description
Delta(9)-tetrahydrocannabinol is a diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. It has a role as a metabolite, a non-narcotic analgesic, a hallucinogen, a cannabinoid receptor agonist and an epitope. It is a diterpenoid, a benzochromene, a polyketide and a phytocannabinoid.
Classification
Small molecule
Drug classcannabinol derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21
Identifiers
PDB—
CAS-ID1972-08-3
RxCUI—
ChEMBL IDCHEMBL465
ChEBI ID66964
PubChem CID16078
DrugBankDB00470
UNII ID7J8897W37S (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GLRA2
GLRA2
Organism
Homo sapiens
Gene name
GLRA2
Gene synonyms
NCBI Gene ID
2742
Protein name
glycine receptor subunit alpha-2
Protein synonyms
glycine receptor alpha 2 subunit, glycine receptor, alpha-2 polypeptide
Uniprot ID
Q99862
Mouse ortholog
Glra2 (237213)
glycine receptor subunit alpha-2 (Q7TNC8)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Syndros – Insys Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dronabinol – Insys Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dronabinol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 41,835 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,179 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use